Antibody-Drug Conjugate (ADC) Market 2026: Pipeline, Deals & Licensing Opportunities.

Antibody–drug conjugates have become one of the fastest-growing modalities in oncology. In 2025 the nine leading products with reported figures generated about $14.3 billion in sales, and the field added two new FDA-approved molecules, a returning one and a string of earlier-line indications. Dealmaking followed: big pharma bought next-generation platforms outright and licensed a steady flow of China-originated assets for global development.

The commercial centre of gravity is Enhertu, Daiichi Sankyo and AstraZeneca’s HER2-directed ADC, which recorded $4.98 billion in combined 2025 sales and moved into early breast cancer in May 2026. Behind it, TROP2, Nectin-4, CD79b and FRα products have each built meaningful franchises, while about 400 ADCs are in clinical development. For business development teams, the opportunity sits in differentiated targets, new payload and conjugation platforms, and combinations that move ADCs into earlier lines of therapy.

/ 01 The ADC market at a glance

• New approvals: Datroway (TROP2, January 2025), Emrelis (c-Met, May 2025) and Decnupaz (CD123, May 2026) joined the US market, and Blenrep returned in October 2025.
• Earlier lines: Enhertu in first-line HER2+ and early breast cancer, Trodelvy and Datroway in first-line TNBC, and Padcev with Keytruda before and after bladder surgery.
• China: four China-originated ADCs won NMPA approval in 2025 and the first half of 2026, including the world’s first approved bispecific ADC.
• Deals: Gilead paid $3.15 billion upfront for Tubulis and Novartis agreed to pay $1.1 billion for Myricx Bio, while Pfizer, Takeda, Roche and Astellas licensed China-originated ADCs.

/ 02 FDA-approved ADCs (October 2026)

Sixteen ADCs have received FDA approval since Mylotarg in 2000. Fifteen are on the US market today; Lumoxiti was withdrawn in 2023. The table lists each with its target and the latest regulatory milestones from the FDA’s oncology approval record.

* Mylotarg and Blenrep were withdrawn and later re-approved. Outside the US, China’s NMPA and Japan’s PMDA have approved further ADCs, bringing the worldwide total to 23 as of June 30, 2026.

/ 03 2025 sales by product

Market-research estimates of the ADC market disagree because they use different product sets and definitions. The figures below are what the companies themselves reported for full-year 2025. Together these nine products sold about $14.3 billion, with Enhertu accounting for roughly 35%.

Roche figures converted at the 2025 average rate of 0.8305 CHF per US dollar (Federal Reserve). The total excludes Takeda’s and Astellas’ ex-US sales of Adcetris and Padcev, Datroway (launched 2025), Blenrep, Besponsa, Mylotarg and China-only products, so the true market is larger.

Three patterns stand out. Growth is concentrated in products moving into earlier lines: Polivy rose 38% on its first-line lymphoma label and Elahere 44% after full approval in ovarian cancer. Enhertu’s expansion from HER2-positive into HER2-low and HER2-ultralow breast cancer carried it from $2.57 billion in 2023 to $3.75 billion in 2024 and $4.98 billion in 2025. And older franchises are not guaranteed: Adcetris fell 17% in Pfizer’s reporting.

/ 04 What drives market growth

The single largest driver is ADCs moving out of late-line salvage settings. Between late 2025 and mid-2026 the FDA approved Enhertu with pertuzumab as first-line therapy for metastatic HER2-positive breast cancer, two Enhertu indications in early breast cancer, Datroway and Trodelvy in first-line triple-negative breast cancer, and Padcev with Keytruda before and after cystectomy in muscle-invasive bladder cancer.

Combinations with immunotherapy are the second driver. In the EV-302 trial, Padcev plus Keytruda cut the risk of death by 53% versus chemotherapy in first-line urothelial cancer (hazard ratio 0.47; median overall survival 31.5 vs 16.1 months), which made the regimen the standard of care. The next wave pairs ADCs with PD-1×VEGF bispecifics: in October 2026 Daiichi Sankyo and AstraZeneca agreed a clinical collaboration with Summit Therapeutics to test Datroway with ivonescimab, starting with a Phase 3 trial in first-line triple-negative breast cancer, and AbbVie cited combinations with its own ADCs when it licensed RemeGen’s PD-1×VEGF bispecific in January 2026. Our PD-1/VEGF bispecific landscape covers that class.

New targets and modalities are the third. B7-H3, CLDN18.2, CDH17 and bispecific formats are widening the addressable tumour types beyond breast cancer and lymphoma, as the pipeline section shows.

/ 05 Pipeline: about 400 ADCs in the clinic

Hanson Wade’s Beacon database tracked 2,334 antibody-based conjugates as of January 5, 2026. Roughly 17% are in active clinical development, about 400 programs, and a record 130 new candidates entered the clinic in 2025, 49% more than the year before.

Targets to watch

• HER2, TROP2, B7-H3 and CLDN18.2 dominate single-target pipelines. HER2 has the largest cohort of clinical-stage ADCs.
• CDH17 was the breakout target of 2025, growing from 6 to 22 tracked candidates with 10 in clinical studies by year-end. No CDH17 therapy is approved yet.
• DLL3 regained momentum after tarlatamab’s success, with six new ADC programs entering development.
• Bispecific pairs: c-MET×EGFR leads with 24 candidates, and Nectin-4×TROP2 constructs from Akeso and Avenzo entered the clinic in 2025.

Late-stage programs: B7-H3 shows both sides of the risk

Three China-originated ADCs were under NMPA review by mid-2026: Innovent’s CLDN18.2 ADC IBI343 (partnered with Takeda), DualityBio’s HER2 ADC DB-1303 (BioNTech) and LaNova’s CLDN18.2 ADC LM-302.

September 2026 brought two opposite B7-H3 outcomes in small cell lung cancer. MediLink’s tambotatug pelitecan (YL201), licensed to Roche outside China, met its overall-survival endpoint in the Phase 3 TAISHAN-302 trial, cutting the risk of death by 54% versus topotecan in Chinese patients with relapsed disease. In the same month Daiichi Sankyo and Merck withdrew their accelerated-approval application for ifinatamab deruxtecan (I-DXd) after FDA discussions concluded the Phase 2 data were not sufficient for accelerated approval; its Phase 3 IDeate-Lung02 trial continues. For buyers, the lesson is to price late-stage assets on randomised evidence rather than response rates alone.

/ 06 Deal landscape 2023–2026

ADC dealmaking runs on two tracks: acquisitions of platforms that can produce many molecules, and licenses of individual, clinically de-risked assets, increasingly from China. The table lists the landmark transactions with their disclosed terms; our biotech licensing deal tracker and pharma M&A tracker cover the wider market.

Dates are announcement dates. “Up to” values include contingent milestones that may never be paid. RemeGen’s January 2026 license to AbbVie ($650m upfront) is left out because the asset is a PD-1×VEGF bispecific antibody, not an ADC.

Case study: how one platform earned three mega-deals

Daiichi Sankyo’s DXd linker-payload technology shows why buyers pay for platforms. AstraZeneca licensed Enhertu in March 2019 for $1.35 billion upfront and up to $6.9 billion in total, then returned in July 2020 for datopotamab deruxtecan with $1 billion upfront and up to $6 billion. In October 2023 Merck committed $4 billion upfront, up to $22 billion in total, for three more DXd ADCs. Each deal priced in the platform’s growing clinical validation, and Enhertu’s sales almost doubled between 2023 and 2025. The I-DXd setback in 2026 is a reminder that a validated platform does not make every molecule a success.

/ 07 Technology generations

• First generation: random conjugation, less stable linkers and DNA-damaging or maytansinoid payloads with a narrow therapeutic window. Examples: Mylotarg, Kadcyla.
• Second generation: protease-cleavable valine-citrulline linkers carrying auristatin (MMAE) payloads at a drug-to-antibody ratio (DAR) near 4. Examples: Adcetris, Polivy, Padcev.
• Third generation: topoisomerase-I inhibitor payloads at higher DAR with a bystander effect that reaches neighbouring tumour cells. Examples: Enhertu (DAR 8), Trodelvy (DAR 7.6), Datroway.
• Next generation: bispecific targeting, dual payloads, new payload mechanisms such as Myricx’s N-myristoyltransferase inhibitors, and low-DAR, high-potency designs. Topoisomerase-I and tubulin payloads still account for about 80% of clinical licensing agreements, which is why differentiated payload platforms command premium prices.

/ 08 ADCs vs conventional chemotherapy

/ 09 China’s ADC engine

China has moved from fast follower to an originator of first-in-class ADCs. Between 2025 and the first half of 2026, the NMPA approved four China-originated ADCs: Hengrui’s trastuzumab rezetecan, Kelun-Biotech’s trastuzumab botidotin, Lepu Biopharma’s becotatug vedotin and Baili Pharmaceutical’s izalontamab brengitecan. The last, partnered with BMS outside China, became the world’s first approved bispecific ADC in June 2026.

Global buyers have followed. Astellas, Roche, Takeda, Pfizer and Pathos AI all licensed China-originated ADCs between 2025 and 2026, typically taking rights outside Greater China while the originator keeps the home market. Across all modalities, Chinese drugmakers signed a record $135.7 billion in cross-border out-licensing deals across 157 agreements in 2025. Our China out-licensing report breaks that total down, and our guide to in-licensing biotech assets from China covers the sourcing process.

Three sourcing patterns

1. Indication gap-fill. Late-stage assets that complete a buyer’s portfolio in an indication where it is underweight. These deals tend to be upfront-weighted.
2. Platform extension. Earlier assets acquired with the know-how behind them. Milestone-weighted structures dominate because the value is in optionality.
3. Geographic license-back. The buyer takes ex-China rights and the seller keeps Greater China, often with co-development clauses and royalty-led economics.

Matching the term sheet to the pattern matters: a license-back priced like a late-stage gap-fill rarely survives negotiation. Our cross-border term sheet guide covers the mechanics.

Three diligence questions that decide value

• Is the trial population translatable? Chinese pivotal studies may use comparators and prior-therapy profiles that differ from US and EU practice. Read the design through the buyer’s regulatory and reimbursement lens.
• Can supply move outside China? Antibody, linker, payload, conjugation and fill-finish must transfer as one system. US BIOSECURE legislation adds scrutiny of manufacturing partners.
• Does the IP travel? Estates filed mainly in China can leave gaps in the buyer’s markets. A current freedom-to-operate opinion and coverage of linker-payload know-how belong in the diligence checklist.

/ 10 BD and licensing strategy

In-licensing priorities

• Underserved targets: CDH17, DLL3 and B7-H3 programs where competition is still forming.
• Platform technology: new payload classes, site-specific conjugation and dual-payload designs. Gilead (Tubulis), Novartis (Myricx) and Taiho (Araris) all moved to buy platforms rather than single molecules.
• Bispecific ADCs: eight Phase 3 starts in 2025 and the first approval in June 2026 have validated the format, but about a quarter of bispecific ADC candidates were discontinued or went inactive in 2025, so manufacturability deserves early diligence.
• Combination-ready assets: ADCs with data or a clear rationale alongside PD-1 or PD-1×VEGF backbones.

Out-licensing opportunities

• Ex-China rights for clinical-stage assets with globally relevant data packages.
• Payload and linker licensing to multiple ADC developers on a non-exclusive basis.
• Regional rights for approved or late-stage ADCs in markets where the originator lacks commercial reach.

Vision Lifesciences advises buyers and sellers on cross-border ADC transactions, from in-licensing searches and asset diligence to out-licensing campaigns and deal structuring.

/ 11 What to watch next

• B7-H3 in small cell lung cancer: Roche’s global plans for tambotatug pelitecan after its positive Phase 3 in China, and IDeate-Lung02 results for I-DXd.
• NMPA decisions on IBI343, DB-1303 and LM-302, filed between April and June 2026.
• Enhertu in lung cancer: DESTINY-Lung04 showed a statistically significant progression-free survival benefit (median 14.3 months) as first-line therapy for HER2-mutant NSCLC.
• ADC plus PD-1×VEGF combinations, starting with Datroway and ivonescimab.
• Integration of 2026 acquisitions: Gilead’s Tubulis programs and Novartis’ Myricx platform.

/ 12 Frequently asked questions